Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct 1;296(1):106-12.
doi: 10.1016/j.canlet.2010.04.003. Epub 2010 May 8.

Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption

Affiliations

Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption

Tiancheng Liu et al. Cancer Lett. .

Abstract

Prostate-specific membrane antigen (PSMA), an established enzyme-biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications. We aimed to determine the effects of PSMA-targeted photodynamic therapy (PDT) on cytoskeletal networks in prostate cancer cells. PSMA-targeted PDT resulted in rapid disruption of microtubules (alpha-/beta-tubulin), microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm of LNCaP cells. The collapse of cytoplasmic microtubules and the later nuclear translocation of alpha-/beta-tubulin were the most dramatic alternation. It is likely that these early changes of cytoskeletal networks are partly involved in the initiation of cell death.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Dr. Berkman is the inventor of a patent on the PSMA inhibitor described in this report and presently serves as the CSO of Cancer Targeted Technology.

Figures

Fig. 1
Fig. 1
Structures of Ppa and Ppa-CTT-54.
Fig. 2
Fig. 2
Changes of α-tubulin and β-tubulin in LNCaP cells after targeted PDT with Ppa-CTT-54.0. (A) Immunofluorescence analysis: targeted PDT induced the rearrangement of microtubules (red) to ring-like perinuclear structures following PDT (0, 15, 30 min). (B) The nucleolar tanslocation of α- and β-tubulin (red) at 1 h or 2 h post-PDT. The nuclei were counterstained with H342 (blue). The cellular imaging was visualized by confocal microscopy; distance scale is 20 µm.
Fig. 3
Fig. 3
Changes of actin in LNCaP cells after targeted PDT with Ppa-CTT-54.0. (A) F/G actin staining: cytoplasmic G-actin (green) was immediately destroyed following PDT. In contrast, the F-actin (red) appeared mainly beneath the cellular membrane and persisted longer than G-actin. (B) Immunofluorescence detection of actin: normal cytoplamic and membrane distribution of actin (green) in the control cells with a rapid loss of cytoplasmic actin and slower loss of membrane-localized actin in PDT-treated cells with increasing time (0, 15 and 30 min) following PDT. The nuclei were stained with H342 (blue). The cellular imaging was visualized with a confocal microscopy; distance scale is 20 µm. (C) Western blot analysis: the amount of actin decreased in PDT-treated cells following PDT (0, 15, 30 min), compared to control cells (C). An increase of cleaved actin was observed in PDT-treated cells.
Fig. 4
Fig. 4
Changes of cytokeratin 8 and 18 in LNCaP cells after targeted PDT with Ppa-CTT-54.0. (A) Immunofluorescence analysis: targeted PDT induced the immediate loss of cytoplasmic intermediate filament networks (cytokeratin 8 and 18, red). A small increase of membrane-localized Cytokeratin 8 and 18 was observed in PDT-treated cells (0, 15 and 30 min). Cell nuclei were stained with H342 (blue). The cellular imaging was visualized with a confocal microscopy; distance scale is 20 µm. (B) Western blot analysis: compared to the control sample, the amount of aggregated (irreversible) and cleaved cytokeratin 8 increased in PDT-treated cell samples following PDT (0, 15, 30 min). In contrast, cytokeratin 18 remained stable except for a small increase of aggregated forms (irreversible) in PDT-treated cell samples.
Figure 5
Figure 5

Similar articles

Cited by

References

    1. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis and Photodynamic Therapy. 2004;1:27–42. - PubMed
    1. Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev. 2004;56:53–76. - PubMed
    1. Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. Journal of medicinal chemistry. 2004;47:3897–3915. - PubMed
    1. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BO, Angell-Petersen E, Warloe T, Frandsen N, Hogset A. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc. 2005;218:133–147. - PubMed
    1. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer--a review of current status and future promise. Nature clinical practice. Urology. 2009;6:18–30. - PubMed

Publication types

MeSH terms